SG10201407357PA - Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis - Google Patents
Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesisInfo
- Publication number
- SG10201407357PA SG10201407357PA SG10201407357PA SG10201407357PA SG10201407357PA SG 10201407357P A SG10201407357P A SG 10201407357PA SG 10201407357P A SG10201407357P A SG 10201407357PA SG 10201407357P A SG10201407357P A SG 10201407357PA SG 10201407357P A SG10201407357P A SG 10201407357PA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- phosphate receptor
- chiral synthesis
- sphingosine
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
- A01N43/74—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,3
- A01N43/78—1,3-Thiazoles; Hydrogenated 1,3-thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/12—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom
- C07C245/14—Diazo compounds, i.e. compounds having the free valencies of >N2 groups attached to the same carbon atom having diazo groups bound to acyclic carbon atoms of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND METHODS OF CHIRAL SYNTHESIS Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the SlP receptor. Methods of chiral synthesis of such compounds is provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated. No Figure
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26130109P | 2009-11-13 | 2009-11-13 | |
US26247409P | 2009-11-18 | 2009-11-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201407357PA true SG10201407357PA (en) | 2014-12-30 |
Family
ID=43992106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201407357PA SG10201407357PA (en) | 2009-11-13 | 2010-11-15 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Country Status (30)
Country | Link |
---|---|
US (4) | US8362048B2 (en) |
EP (3) | EP2498610B1 (en) |
JP (3) | JP5650233B2 (en) |
KR (2) | KR101752124B1 (en) |
CN (2) | CN105061350B (en) |
AU (1) | AU2010319983B2 (en) |
BR (2) | BR112012011427B8 (en) |
CA (2) | CA2780772C (en) |
CY (3) | CY1120338T1 (en) |
DK (2) | DK3406142T3 (en) |
EA (2) | EA024801B1 (en) |
ES (2) | ES2673160T3 (en) |
FR (1) | FR20C1059I2 (en) |
HK (2) | HK1175948A1 (en) |
HR (2) | HRP20180874T1 (en) |
HU (3) | HUE037535T2 (en) |
IL (2) | IL219691B (en) |
LT (3) | LT2498610T (en) |
MX (1) | MX2012005560A (en) |
MY (2) | MY161854A (en) |
NO (2) | NO2498610T3 (en) |
NZ (1) | NZ599915A (en) |
PH (1) | PH12015502708B1 (en) |
PL (2) | PL3406142T3 (en) |
PT (2) | PT2498610T (en) |
RS (2) | RS61829B1 (en) |
SG (1) | SG10201407357PA (en) |
SI (2) | SI2498610T1 (en) |
TR (1) | TR201807912T4 (en) |
WO (1) | WO2011060392A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102724880B (en) * | 2009-11-13 | 2016-09-14 | 瑞塞普托斯有限责任公司 | S1P receptor modulators and Chiral Synthesis |
EA024801B1 (en) | 2009-11-13 | 2016-10-31 | Рецептос Ллк | Selective sphingosine 1 phosphate receptor modulators |
WO2012158550A2 (en) | 2011-05-13 | 2012-11-22 | Receptos, Inc. | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
BR112014031565B1 (en) * | 2012-06-21 | 2022-04-12 | Eisai R&D Management Co., Ltd | Innovative indanesulfamide derivative |
WO2014158302A1 (en) * | 2013-03-25 | 2014-10-02 | Swenson Rolf Eric | Novel sphingosine 1-phosphate receptor antagonists |
US20170165236A1 (en) * | 2013-11-01 | 2017-06-15 | Celgene International Ii Sàrl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
WO2016164180A1 (en) | 2015-04-06 | 2016-10-13 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
EP3470400A1 (en) * | 2016-06-14 | 2019-04-17 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of ozanimod, crystal form of hydrochloride thereof, and preparation method therefor |
WO2018014862A1 (en) * | 2016-07-22 | 2018-01-25 | 南京明德新药研发股份有限公司 | S1p1 agonist and application thereof |
WO2018033149A1 (en) * | 2016-08-19 | 2018-02-22 | 苏州科睿思制药有限公司 | Crystal forms of ozanimod and preparation method therefor |
WO2018050091A1 (en) | 2016-09-14 | 2018-03-22 | 苏州科睿思制药有限公司 | Crystal form of ozanimod hydrochloride, and preparation method therefor |
WO2018049632A1 (en) * | 2016-09-14 | 2018-03-22 | 杭州领业医药科技有限公司 | Crystal form of ozanimod, and preparation method and pharmaceutical composition thereof |
CA3038106A1 (en) * | 2016-09-29 | 2018-04-05 | Celgene International Ii Sarl | Compounds and methods for treating lupus |
US10981900B2 (en) * | 2017-02-28 | 2021-04-20 | Medshine Discovery Inc. | Spiro compound and use thereof |
WO2018184185A1 (en) * | 2017-04-07 | 2018-10-11 | 杭州领业医药科技有限公司 | Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses |
CN108727291A (en) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | The preparation method of Ao Zhamode and its intermediate |
CN108727292A (en) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | A kind of preparation method of Ao Zhamode and its intermediate |
US11207301B2 (en) | 2017-05-08 | 2021-12-28 | Receptos Llc | Sphingosine 1 phosphate receptor agonists for neuroprotection |
HUE064642T2 (en) * | 2017-05-22 | 2024-04-28 | Egis Gyogyszergyar Zrt | Process for the production of ozanimod |
US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
US10675255B2 (en) | 2017-06-23 | 2020-06-09 | Enzo Bochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
CN109280035B (en) * | 2017-07-19 | 2023-06-09 | 广东东阳光药业有限公司 | Polymorphic forms of ozagrel and processes for their preparation |
EP3677575A4 (en) * | 2017-08-31 | 2020-07-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystalline form of ozanimod hydrochloride and preparation method therefor |
WO2019058290A1 (en) * | 2017-09-20 | 2019-03-28 | Suven Life Sciences Limited | Improved process for the preparation of ozanimod α-amino compound |
WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
CN107857760A (en) * | 2017-11-21 | 2018-03-30 | 南京天翔医药科技有限公司 | The phosphate receptor modulators of sphingol 1 and its application |
US11465995B2 (en) | 2018-01-18 | 2022-10-11 | Medshine Discovery Inc. | Crystal and salt forms of tricyclic compound and preparation process thereof |
EP3769759B1 (en) | 2018-03-20 | 2023-11-15 | Eisai R&D Management Co., Ltd. | Combination of an indanesulfamide derivative with perampanel for use in the treatment of epilepsy |
CN110615747A (en) * | 2018-06-20 | 2019-12-27 | 广东东阳光药业有限公司 | Preparation method of indane intermediate |
CA3109673A1 (en) | 2018-09-12 | 2020-03-19 | Pharmazell Gmbh | A process for the preparation of ozanimod and its intermediate (s)-1-amino-2,3-dihydro-1h-indene-4-carbonitrile |
AR116479A1 (en) * | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | INTERMEDIARIES FOR THE SYNTHESIS OF OZANIMOD AND PROCEDURE FOR THE PREPARATION OF THE MENTIONED SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST AND SUCH INTERMEDIARIES |
US11390593B2 (en) | 2018-12-07 | 2022-07-19 | Synthon B.V. | Process for preparing ozanimod |
KR20210150371A (en) * | 2019-03-29 | 2021-12-10 | 리셉토스 엘엘씨 | sphingosine 1 phosphate receptor modulator |
WO2020205478A1 (en) * | 2019-03-29 | 2020-10-08 | Celgene International Ii Sarl | Sphingosine 1 phosphate receptor modulators |
KR20210151068A (en) * | 2019-03-29 | 2021-12-13 | 리셉토스 엘엘씨 | sphingosine 1 phosphate receptor modulator |
WO2020219207A1 (en) * | 2019-04-26 | 2020-10-29 | Celgene International Ii Sarl | Sphingosine 1 phosphate receptor modulator |
CN112062785B (en) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | Preparation method of ozagrel and intermediate thereof |
MX2022000651A (en) | 2019-07-16 | 2022-03-11 | Synthon Bv | Improved process for preparing ozanimod. |
CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
IL294071A (en) * | 2020-01-06 | 2022-08-01 | Arena Pharm Inc | Methods of treating conditions related to the s1p1 receptor |
JP7443550B2 (en) | 2020-03-04 | 2024-03-05 | ヒーリオイースト ファーマシューティカル カンパニー リミテッド | Tricyclic compounds and their uses |
JP7307282B2 (en) * | 2020-03-04 | 2023-07-11 | ヒーリオイースト ファーマシューティカル カンパニー リミテッド | Benzo 2-azaspiro[4.4]nonane compounds and uses thereof |
EP4121025A4 (en) | 2020-03-17 | 2024-03-27 | Enzo Biochem Inc | Sphingosine pathway modulating compounds for the treatment of coronavirus infection |
WO2021197852A1 (en) | 2020-04-02 | 2021-10-07 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
CN111620788B (en) * | 2020-04-20 | 2022-09-30 | 广东莱佛士制药技术有限公司 | Method for preparing (2S,3S) -3-amino-bicyclo [2.2.2] octane-2-formic ether |
CN116867771A (en) * | 2021-04-09 | 2023-10-10 | 南昌弘益药业有限公司 | Oxadiazole substituted spiro compounds and application thereof |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
FR2628103B1 (en) * | 1988-03-03 | 1991-06-14 | Roussel Uclaf | NOVEL PYRETHRINOID ESTERS CARRYING AN INDANYL CORE, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS PESTICIDES |
US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
EP0583346A1 (en) | 1991-04-12 | 1994-02-23 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
GB2290790A (en) | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
DE69911176T2 (en) * | 1998-01-23 | 2004-06-24 | Sankyo Co., Ltd. | Spiropiperidine DERIVATIVES |
US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
AU2003297232B2 (en) | 2002-12-20 | 2010-02-04 | Merck Sharp & Dohme Corp. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles |
ES2770035T3 (en) | 2003-04-11 | 2020-06-30 | Ptc Therapeutics Inc | 1,2,4-Oxadiazole benzoic acid compound and its use for senseless suppression and treatment of diseases |
CN1859908A (en) * | 2003-10-01 | 2006-11-08 | 默克公司 | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists |
JP4773972B2 (en) | 2003-12-17 | 2011-09-14 | メルク・シャープ・エンド・ドーム・コーポレイション | (3,4-Disubstituted) propanecarboxylic acids as S1P (Edg) receptor agonists |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
JP2008531546A (en) | 2005-02-22 | 2008-08-14 | テバ ファーマシューティカル インダストリーズ リミティド | An improved process for the synthesis of enantiomeric indanylamine derivatives |
KR100667075B1 (en) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | Scan driver and organic electroluminescence display device of having the same |
EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
PE20070705A1 (en) * | 2005-11-25 | 2007-08-23 | Basf Ag | INDANIL - AND TETRAHIDRONAFTIL-AMINO-AZOLINE COMPOUNDS TO FIGHT ANIMAL PESTS |
EP1963509A4 (en) | 2005-12-21 | 2009-07-29 | Joseph Gabriele | Catecholamine regulated protein |
US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
US20080009534A1 (en) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
RU2442780C2 (en) * | 2006-09-21 | 2012-02-20 | Актелион Фармасьютиклз Лтд | Phenyl derivatives and their application as immunomodulators |
AU2007323540A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
AU2007334436A1 (en) * | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Compounds |
WO2008106224A1 (en) | 2007-02-28 | 2008-09-04 | Rib-X Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
US20090298894A1 (en) | 2008-04-21 | 2009-12-03 | Asahi Kasei Pharma Corporation | Amino acid compounds |
NZ589617A (en) * | 2008-05-14 | 2012-06-29 | Scripps Research Inst | 3-(Inden-4-yl)-5-(phenyl)-1,2,4-oxadiazole and 3-(tetralin-5-yl)-5-(phenyl)-1,2,4-oxadiazole derivatives |
WO2009151259A1 (en) * | 2008-06-13 | 2009-12-17 | 두원공과대학교 | Reciprocating compressor with rotary valve |
GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
GB0911130D0 (en) | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
EA024801B1 (en) | 2009-11-13 | 2016-10-31 | Рецептос Ллк | Selective sphingosine 1 phosphate receptor modulators |
EP2498609B1 (en) | 2009-11-13 | 2018-04-18 | Celgene International II Sàrl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
CN102724880B (en) * | 2009-11-13 | 2016-09-14 | 瑞塞普托斯有限责任公司 | S1P receptor modulators and Chiral Synthesis |
WO2012158550A2 (en) | 2011-05-13 | 2012-11-22 | Receptos, Inc. | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
WO2013055907A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
-
2010
- 2010-11-15 EA EA201290323A patent/EA024801B1/en not_active IP Right Cessation
- 2010-11-15 SI SI201031704T patent/SI2498610T1/en unknown
- 2010-11-15 NO NO10830880A patent/NO2498610T3/no unknown
- 2010-11-15 CN CN201510295907.XA patent/CN105061350B/en active Active
- 2010-11-15 LT LTEP10830880.0T patent/LT2498610T/en unknown
- 2010-11-15 DK DK18160667.4T patent/DK3406142T3/en active
- 2010-11-15 PL PL18160667T patent/PL3406142T3/en unknown
- 2010-11-15 RS RS20210360A patent/RS61829B1/en unknown
- 2010-11-15 SI SI201032063T patent/SI3406142T1/en unknown
- 2010-11-15 EA EA201690391A patent/EA035768B1/en not_active IP Right Cessation
- 2010-11-15 HU HUE10830880A patent/HUE037535T2/en unknown
- 2010-11-15 BR BR112012011427A patent/BR112012011427B8/en active IP Right Grant
- 2010-11-15 NZ NZ599915A patent/NZ599915A/en unknown
- 2010-11-15 ES ES10830880.0T patent/ES2673160T3/en active Active
- 2010-11-15 DK DK10830880.0T patent/DK2498610T3/en active
- 2010-11-15 PT PT108308800T patent/PT2498610T/en unknown
- 2010-11-15 SG SG10201407357PA patent/SG10201407357PA/en unknown
- 2010-11-15 MY MYPI2012002084A patent/MY161854A/en unknown
- 2010-11-15 MY MYPI2016002092A patent/MY189750A/en unknown
- 2010-11-15 EP EP10830880.0A patent/EP2498610B1/en active Active
- 2010-11-15 TR TR2018/07912T patent/TR201807912T4/en unknown
- 2010-11-15 CA CA2780772A patent/CA2780772C/en active Active
- 2010-11-15 KR KR1020167035297A patent/KR101752124B1/en active IP Right Grant
- 2010-11-15 LT LTEP18160667.4T patent/LT3406142T/en unknown
- 2010-11-15 JP JP2012539065A patent/JP5650233B2/en active Active
- 2010-11-15 PL PL10830880T patent/PL2498610T3/en unknown
- 2010-11-15 BR BR122018077504A patent/BR122018077504B8/en active IP Right Grant
- 2010-11-15 EP EP18160667.4A patent/EP3406142B8/en active Active
- 2010-11-15 MX MX2012005560A patent/MX2012005560A/en active IP Right Grant
- 2010-11-15 EP EP20215106.4A patent/EP3868377A1/en not_active Withdrawn
- 2010-11-15 US US12/946,819 patent/US8362048B2/en active Active
- 2010-11-15 AU AU2010319983A patent/AU2010319983B2/en active Active
- 2010-11-15 RS RS20180647A patent/RS57253B1/en unknown
- 2010-11-15 PT PT181606674T patent/PT3406142T/en unknown
- 2010-11-15 CA CA2986521A patent/CA2986521C/en active Active
- 2010-11-15 HU HUE18160667A patent/HUE054000T2/en unknown
- 2010-11-15 CN CN201080061144.8A patent/CN102762100B/en active Active
- 2010-11-15 ES ES18160667T patent/ES2858337T3/en active Active
- 2010-11-15 KR KR1020127015292A patent/KR101721716B1/en active IP Right Grant
- 2010-11-15 WO PCT/US2010/056760 patent/WO2011060392A1/en active Application Filing
-
2012
- 2012-05-09 IL IL219691A patent/IL219691B/en active IP Right Grant
-
2013
- 2013-01-14 US US13/740,661 patent/US20130231326A1/en not_active Abandoned
- 2013-03-14 HK HK13103206.9A patent/HK1175948A1/en unknown
- 2013-03-14 HK HK16100726.3A patent/HK1213874A1/en unknown
- 2013-11-14 JP JP2013235966A patent/JP5982705B2/en active Active
-
2014
- 2014-11-12 JP JP2014229895A patent/JP2015038145A/en active Pending
-
2015
- 2015-02-26 US US14/632,675 patent/US9388147B2/en active Active
- 2015-12-04 PH PH12015502708A patent/PH12015502708B1/en unknown
-
2017
- 2017-01-13 US US15/406,128 patent/US10239846B2/en active Active
-
2018
- 2018-06-05 HR HRP20180874TT patent/HRP20180874T1/en unknown
- 2018-06-12 CY CY20181100611T patent/CY1120338T1/en unknown
-
2019
- 2019-07-09 IL IL267956A patent/IL267956B/en active IP Right Grant
-
2020
- 2020-11-18 FR FR20C1059C patent/FR20C1059I2/en active Active
- 2020-11-18 NO NO2020039C patent/NO2020039I1/en unknown
- 2020-11-18 LT LTPA2020533C patent/LTC2498610I2/en unknown
- 2020-11-18 HU HUS2000045C patent/HUS2000045I1/en unknown
- 2020-11-19 CY CY2020035C patent/CY2020035I1/en unknown
-
2021
- 2021-03-17 HR HRP20210446TT patent/HRP20210446T1/en unknown
- 2021-03-22 CY CY20211100241T patent/CY1124121T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502708A1 (en) | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
MX2012005559A (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators. | |
MY160907A (en) | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis | |
WO2012158550A3 (en) | Selective heterocyclic sphingosine 1 phosphate receptor modulators | |
MX2013004508A (en) | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease. | |
MY156381A (en) | Novel modulators of sphingosine phosphate receptors | |
EA019970B8 (en) | Imidazolidinedione derivatives | |
EA201071245A1 (en) | NEW THERAPEUTIC APPROACHES FOR THE TREATMENT OF ALZGEYMER'S DISEASE AND RELATED DISTURBANCES THROUGH MODULATION OF THE STRESS RESPONSE | |
MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
MX2020012825A (en) | Multicyclic compounds and methods of use thereof. | |
HK1136283A1 (en) | Compounds for the prevention and treatment of cardiovascular diseases | |
WO2009076454A3 (en) | Compounds that modulate intracellular calcium | |
MX2018015635A (en) | Compositions and methods for modulation of smn2 splicing in a subject. | |
MX2010007490A (en) | Preparation of sulfamide derivatives. | |
MX2011006150A (en) | Kinase inhibitor compounds. | |
MX368459B (en) | Novel compositions for preventing and/or treating degenerative disorders of the central nervous system. | |
MX2009011421A (en) | Phthalazine and isoquinoline derivatives with slp receptor modulating activities. | |
TN2012000610A1 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
WO2011147034A8 (en) | Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof | |
MX2009013197A (en) | Therapeutic pyrazolonaphthyridine derivatives. | |
MX2010001501A (en) | Gamma secretase modulators. | |
HK1146628A1 (en) | 1,2,4,-triazin-3,5-dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor | |
DE602008002598D1 (en) | Cyclohexylderivate | |
MX2009012716A (en) | New disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission. | |
WO2010147969A3 (en) | Gamma secretase modulators |